Make sure to stay updated. HAEi will keep you informed when you sign up for our newsletter.
Sign up for HAEi Newsletter and register at the same time.
Route de Crassier
Shire Human Genetic Therapies (HGT) is a business unit of Shire plc, the global biopharmaceutical company. Shire HGT is committed to developing, manufacturing, and commercializing therapies for life-threatening genetic diseases. The company achieves this through collaboration with academic researchers, physicians and patient associations, providing therapies for patients worldwide.
Shire ‘s icatibant (trade name: Firazyr) is a B2 bradykinin receptor antagonist. The German biotechnology company Jerini AG (acquired by Shire HGT) did develop icatibant which following a successful study in Europe got approved by EMA for treatment of HAE attacks in all 27 EU countries. Since then new trials has led to approval also by the FDA for treatment of HAE attacks in the US. Both in Europe and in the US, Firazyr is registered for self administration.Shire is currently also working on making Firazyr available in other parts of the world.